We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
- Authors
Yamamoto, Noboru; Goto, Koichi; Nishio, Makoto; Chikamori, Kenichi; Hida, Toyoaki; Maemondo, Makoto; Katakami, Nobuyuki; Kozuki, Toshiyuki; Yoshioka, Hiroshige; Seto, Takashi; Tajima, Kosei; Tamura, Tomohide
- Subjects
NON-small-cell lung carcinoma; CANCER treatment; ERLOTINIB; PATIENTS; THERAPEUTICS
- Publication
International Journal of Clinical Oncology, 2017, Vol 22, Issue 1, p79
- ISSN
1341-9625
- Publication type
Erratum
- DOI
10.1007/s10147-016-1052-3